Inflarx N.V. (IFRX) SEC Filings — 2024
16 SEC filings for Inflarx N.V. (IFRX) in 2024.
Filings
- InflaRx Doses First Patient in INF904 Phase 2a Study — 6-K · Dec 20, 2024
- InflaRx N.V. Gets Positive CHMP Opinion for GOHIBIC® — 6-K · Nov 15, 2024
- InflaRx N.V. Files 6-K, Incorporates Exhibits — 6-K · Nov 8, 2024
- InflaRx Files 6-K, Incorporates Exhibits into S-8 Filings — 6-K · Aug 8, 2024
- InflaRx N.V. Launches At-The-Market Share Offering — 6-K · Jun 28, 2024
- InflaRx's GOHIBIC Tapped for BARDA ARDS Trial — 6-K · Jun 24, 2024
- InflaRx N.V. Highlights Promise of INF904 at R&D Event — 6-K · Jun 5, 2024
- InflaRx N.V. Presents COVID-19 Trial Synergy Data — 6-K · May 21, 2024
- InflaRx N.V. 6-K Filing Incorporates Exhibits — 6-K · May 8, 2024
- InflaRx N.V. Approves 2023 Annual Accounts — 6-K · Apr 25, 2024
- InflaRx N.V. Announces Annual Shareholder Meeting — 6-K · Apr 4, 2024
- InflaRx N.V. Files Annual Report on Form 20-F for Fiscal Year Ended December 31, 2023 — 20-F · Mar 21, 2024
- InflaRx Reports 2023 Results, Pipeline Updates — 6-K · Mar 21, 2024
- Inflarx N.V. SC 13G/A Filing — SC 13G/A · Feb 14, 2024
- InflaRx Launches GOHIBIC Commitment Program to Broaden Patient Access — 6-K · Jan 25, 2024
- InflaRx INF904 Phase I Study Shows Positive Topline Results — 6-K · Jan 4, 2024